Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
The closing price of Akebia Therapeutics Inc (NASDAQ: AKBA) was $2.71 for the day, down -2.17% from the previous closing price of $2.77. In other words, the price has decreased by -$2.17 from its previous closing price. On the day, 2.62 million shares were traded. AKBA stock price reached its highest trading level at $2.7799 during the session, while it also had its lowest trading level at $2.69.
Ratios:
Our analysis of AKBA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.84 and its Current Ratio is at 1.98. In the meantime, Its Debt-to-Equity ratio is 7.21 whereas as Long-Term Debt/Eq ratio is at 6.10.
On April 28, 2025, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $7.
On April 01, 2025, Jefferies started tracking the stock assigning a Buy rating and target price of $6.Jefferies initiated its Buy rating on April 01, 2025, with a $6 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jun 30 ’25 when Ostrowski Erik sold 41,314 shares for $3.67 per share. The transaction valued at 151,622 led to the insider holds 503,586 shares of the business.
Ostrowski Erik bought 41,314 shares of AKBA for $151,622 on Jun 30 ’25. On Jun 09 ’25, another insider, Malabre Richard C, who serves as the SVP, Chief Accounting Officer of the company, sold 15,000 shares for $4.01 each. As a result, the insider received 60,150 and left with 266,914 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AKBA now has a Market Capitalization of 718543040 and an Enterprise Value of 777132032. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.53 while its Price-to-Book (P/B) ratio in mrq is 24.39. Its current Enterprise Value per Revenue stands at 3.814 whereas that against EBITDA is 33.285.
Stock Price History:
The Beta on a monthly basis for AKBA is 0.69, which has changed by 1.0375941 over the last 52 weeks, in comparison to a change of 0.15101504 over the same period for the S&P500. Over the past 52 weeks, AKBA has reached a high of $4.08, while it has fallen to a 52-week low of $1.24. The 50-Day Moving Average of the stock is -16.82%, while the 200-Day Moving Average is calculated to be 2.34%.
Shares Statistics:
AKBA traded an average of 3.81M shares per day over the past three months and 3405120 shares per day over the past ten days. A total of 263.04M shares are outstanding, with a floating share count of 251.14M. Insiders hold about 5.28% of the company’s shares, while institutions hold 40.00% stake in the company. Shares short for AKBA as of 1756425600 were 27090731 with a Short Ratio of 7.18, compared to 1753920000 on 24538006. Therefore, it implies a Short% of Shares Outstanding of 27090731 and a Short% of Float of 10.319999600000001.
Earnings Estimates
Akebia Therapeutics Inc (AKBA) is presently subject to a detailed evaluation by 2.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.03, with high estimates of -$0.02 and low estimates of -$0.04.
Analysts are recommending an EPS of between -$0.02 and -$0.04 for the fiscal current year, implying an average EPS of -$0.03. EPS for the following year is $0.26, with 2.0 analysts recommending between $0.41 and $0.11.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 5 analysts. It ranges from a high estimate of $65.5M to a low estimate of $45.54M. As of the current estimate, Akebia Therapeutics Inc’s year-ago sales were $37.43MFor the next quarter, 5 analysts are estimating revenue of $54.1M. There is a high estimate of $76.4M for the next quarter, whereas the lowest estimate is $38.85M.
A total of 5 analysts have provided revenue estimates for AKBA’s current fiscal year. The highest revenue estimate was $261.7M, while the lowest revenue estimate was $204.2M, resulting in an average revenue estimate of $226M. In the same quarter a year ago, actual revenue was $160.18MBased on 5 analysts’ estimates, the company’s revenue will be $298.52M in the next fiscal year. The high estimate is $396.3M and the low estimate is $227.9M.
